The Cas9 editor carried by the gene-edited oncolytic Adv can target and knock out the PD-L1 gene in tumor cells and tumor-infiltrating immunosuppressive cells, reducing their PD-L1 expression levels. This evidence concerns the gene CD274 and neoplasm.